Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 April 2019, 20:00 HKT/SGT
Share:
    

Source: ReShape Lifesciences Inc.
ReShape Lifesciences Announces Distribution in Australia

SAN CLEMENTE, CA & MELBOURNE, AU, Apr 18, 2019 - (ACN Newswire) - ReShape Lifesciences™, a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announces that as of April 1, 2019, the company was selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market.

The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND while it was owned by Allergan and Apollo Endosurgery respectively. Concurrent with this relationship, ReShape Lifesciences has fully taken over all distribution of the LAP-BAND product in Australia from Apollo Endosurgery, Inc. and will subsequently be recognizing revenue from sales of the product in Australia.

Over 120,000 LAP-BAND procedures have taken place in Australia since the product was launched in the country, making Australia one of the largest worldwide markets for LAP-BAND outside of the U.S. Australia was one of the early adopters of the LAP-BAND technology and has produced some of the strongest data and research on the product. According to the OECD 2017 Obesity Update, based on self-reported data, 27.9% of the Australian adult population are obese, the fifth highest obesity rate of any developed country.

About ReShape Lifesciences Inc

ReShape Lifesciences™ (OTCQB: RSLS) is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Investor Contact:
Scott Youngstrom
Chief Financial Officer
ReShape Lifesciences Inc.
+1-949-429-6680 x106
[email protected]

SOURCE: ReShape Lifesciences Inc.


Apr 18, 2019 20:00 HKT/SGT
Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
WeWork, the World's Leading Community, Space and Service Provider, Sets Foot in Chinlink International Centre in Xi'an  
May 22, 2019 19:44 HKT/SGT
ESR enlarges footprint in Singapore REIT market investing in Sabana REIT and its Manager  
May 22, 2019 16:38 HKT/SGT
KDDI and SUMITOMO to enter Myanmar's Mobile Game Industry  
May 22, 2019 14:00 HKT/SGT
ACROMEC Subsidiary Acropower signs with Chew's Agriculture to build-own-operate a Waste-to-Energy Plant  
May 22, 2019 13:00 HKT/SGT
Showa Denko Group Revises CSR Policy  
May 22, 2019 11:00 HKT/SGT
Sino Biopharmaceutical Announces 2019 First Quarterly Results  
May 22, 2019 10:40 HKT/SGT
Global Alliance Partners welcomes new Partner in Korea - KTB Financial Group  
May 22, 2019 09:40 HKT/SGT
3rd World Intelligence Congress (WIC 2019) Stresses AI's Role In Growth  
May 22, 2019 09:00 HKT/SGT
Forbes ranks Eastman as one of the Best Large Employers in America  
May 21, 2019 23:00 HKT/SGT
NetDragon Celebrates 20th Anniversary, Innovation & Technology Driving Strategy Upgrades  
May 21, 2019 20:02 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: